Insider · CIK 0001913245
Kevin Patrick Danahy
Files at PLSE (Pulse Biosciences, Inc.). First filing Nov 17, 2023, latest Feb 23, 2026.
In brief
Kevin Patrick Danahy files SEC Form 4 as CEO at PLSE (Pulse Biosciences, Inc.). Since Nov 17, 2023, Kevin Patrick Danahy has reported 1 open-market buy worth $35k and 5 open-market sells worth $3.4M, the latest filed on Feb 23, 2026.
A track record needs three past buys with six months of prices behind them; Kevin Patrick Danahy has 0, so none is measured yet.
The newest scored trade: sold $118k of PLSE on Feb 18, 2026, filed Feb 23, 2026, scored 0 (weak), under a 10b5-1 plan. In the last 12 months: 0 buys worth $0 and 3 sells worth $2.9M.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
PLSE: Pulse Biosciences, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 0Weak | Pulse Biosciences, Inc. | $118k 5,000 shares | -10% | +101% from low0% from high | |
| 25Weak | Pulse Biosciences, Inc. | $1.4M 60,000 shares | -95% | +85% from low-7% from high | |
| 25Weak | Pulse Biosciences, Inc. | $1.4M 60,000 shares | -95% | +91% from low0% from high | |
| 0Weak | Pulse Biosciences, Inc. | $85k 4,600 shares | -10% | +31% from low-23% from high | |
| 14Weak | Pulse Biosciences, Inc. | $377k 20,400 shares | -32% | +28% from low-25% from high | |
| 53Moderate | Pulse Biosciences, Inc. | $35k 5,393 shares | +18% | +261% from low-29% from high |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Feb 12, 2026 | PLSE PULSE BIOSCIENCES INC | 50,000 0.07% of outstanding | $1.3M | Feb 12, 2026 | $1.4M |
| Feb 9, 2026 | PLSE PULSE BIOSCIENCES INC | 75,000 0.11% of outstanding | $1.6M | Feb 9, 2026 | none |
| Sep 18, 2025 | PLSE PULSE BIOSCIENCES INC | 25,000 0.04% of outstanding | $407k | Sep 18, 2025 | none |
Transactions
Every row this insider has filed, 36 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Feb 18, 2026 | PLSE Pulse Biosciences, Inc. | MOption exercise Common Stock10b5-1 | +5,000 | $1.53 | $7,650 | 48,298 | Feb 23, 2026 |
| Feb 18, 2026 | PLSE Pulse Biosciences, Inc. | SOpen-market sale Common Stock10b5-1 | -5,000 | $23.64 | $118k | 43,298 | Feb 23, 2026 |
| Feb 18, 2026 | PLSE Pulse Biosciences, Inc. | MOption exercise Stock Option (right to buy)derivative10b5-1 | -5,000 | $0.00 | $0 | 300,000 | Feb 23, 2026 |
| Feb 12, 2026 | PLSE Pulse Biosciences, Inc. | MOption exercise Common Stock10b5-1 | +20,000 | $1.53 | $31k | 63,298 | Feb 17, 2026 |
| Feb 12, 2026 | PLSE Pulse Biosciences, Inc. | SOpen-market sale Common Stock10b5-1 | -20,000 | $23.37 | $467k | 43,298 | Feb 17, 2026 |
| Feb 13, 2026 | PLSE Pulse Biosciences, Inc. | MOption exercise Common Stock10b5-1 | +20,000 | $1.53 | $31k | 63,298 | Feb 17, 2026 |
| Feb 13, 2026 | PLSE Pulse Biosciences, Inc. | SOpen-market sale Common Stock10b5-1 | -20,000 | $23.53 | $471k | 43,298 | Feb 17, 2026 |
| Feb 17, 2026 | PLSE Pulse Biosciences, Inc. | MOption exercise Common Stock10b5-1 | +20,000 | $1.53 | $31k | 63,298 | Feb 17, 2026 |
| Feb 17, 2026 | PLSE Pulse Biosciences, Inc. | SOpen-market sale Common Stock10b5-1 | -20,000 | $23.63 | $473k | 43,298 | Feb 17, 2026 |
| Feb 12, 2026 | PLSE Pulse Biosciences, Inc. | MOption exercise Stock Option (right to buy)derivative10b5-1 | -20,000 | $0.00 | $0 | 345,000 | Feb 17, 2026 |
| Feb 13, 2026 | PLSE Pulse Biosciences, Inc. | MOption exercise Stock Option (right to buy)derivative10b5-1 | -20,000 | $0.00 | $0 | 325,000 | Feb 17, 2026 |
| Feb 17, 2026 | PLSE Pulse Biosciences, Inc. | MOption exercise Stock Option (right to buy)derivative10b5-1 | -20,000 | $0.00 | $0 | 305,000 | Feb 17, 2026 |
| Feb 9, 2026 | PLSE Pulse Biosciences, Inc. | MOption exercise Common Stock10b5-1 | +20,000 | $1.53 | $31k | 63,298 | Feb 11, 2026 |
| Feb 9, 2026 | PLSE Pulse Biosciences, Inc. | SOpen-market sale Common Stock10b5-1 | -20,000 | $21.45 | $429k | 43,298 | Feb 11, 2026 |
| Feb 10, 2026 | PLSE Pulse Biosciences, Inc. | MOption exercise Common Stock10b5-1 | +20,000 | $1.53 | $31k | 63,298 | Feb 11, 2026 |
| Feb 10, 2026 | PLSE Pulse Biosciences, Inc. | SOpen-market sale Common Stock10b5-1 | -20,000 | $23.52 | $470k | 43,298 | Feb 11, 2026 |
| Feb 11, 2026 | PLSE Pulse Biosciences, Inc. | MOption exercise Common Stock10b5-1 | +20,000 | $1.53 | $31k | 63,298 | Feb 11, 2026 |
| Feb 11, 2026 | PLSE Pulse Biosciences, Inc. | SOpen-market sale Common Stock10b5-1 | -20,000 | $25.20 | $504k | 43,298 | Feb 11, 2026 |
| Feb 9, 2026 | PLSE Pulse Biosciences, Inc. | MOption exercise Stock Option (right to buy)derivative10b5-1 | -20,000 | $0.00 | $0 | 405,000 | Feb 11, 2026 |
| Feb 10, 2026 | PLSE Pulse Biosciences, Inc. | MOption exercise Stock Option (right to buy)derivative10b5-1 | -20,000 | $0.00 | $0 | 385,000 | Feb 11, 2026 |
| Feb 11, 2026 | PLSE Pulse Biosciences, Inc. | MOption exercise Stock Option (right to buy)derivative10b5-1 | -20,000 | $0.00 | $0 | 365,000 | Feb 11, 2026 |
| Oct 2, 2025 | PLSE Pulse Biosciences, Inc. | MOption exercise Common Stock10b5-1 | +4,600 | $1.53 | $7,038 | 47,898 | Oct 7, 2025 |
| Oct 2, 2025 | PLSE Pulse Biosciences, Inc. | SOpen-market sale Common Stock10b5-1 | -4,600 | $18.53 | $85k | 43,298 | Oct 7, 2025 |
| Oct 2, 2025 | PLSE Pulse Biosciences, Inc. | MOption exercise Stock Option (right to buy)derivative10b5-1 | -4,600 | $0.00 | $0 | 425,000 | Oct 7, 2025 |
| Sep 18, 2025 | PLSE Pulse Biosciences, Inc. | MOption exercise Common Stock10b5-1 | +20,000 | $1.53 | $31k | 63,298 | Sep 22, 2025 |
| Sep 18, 2025 | PLSE Pulse Biosciences, Inc. | SOpen-market sale Common Stock10b5-1 | -20,000 | $18.49 | $370k | 43,298 | Sep 22, 2025 |
| Sep 19, 2025 | PLSE Pulse Biosciences, Inc. | MOption exercise Common Stock10b5-1 | +400 | $1.53 | $612 | 43,698 | Sep 22, 2025 |
| Sep 19, 2025 | PLSE Pulse Biosciences, Inc. | SOpen-market sale Common Stock10b5-1 | -400 | $18.48 | $7,392 | 43,298 | Sep 22, 2025 |
| Sep 18, 2025 | PLSE Pulse Biosciences, Inc. | MOption exercise Stock Option (right to buy)derivative10b5-1 | -20,000 | $0.00 | $0 | 430,000 | Sep 22, 2025 |
| Sep 19, 2025 | PLSE Pulse Biosciences, Inc. | MOption exercise Stock Option (right to buy)derivative10b5-1 | -400 | $0.00 | $0 | 429,600 | Sep 22, 2025 |
| Nov 16, 2023 | PLSE Pulse Biosciences, Inc. | POpen-market purchase Common Stock | +4,781 | $6.52 | $31k | 35,275 | Nov 17, 2023 |
| Nov 16, 2023 | PLSE Pulse Biosciences, Inc. | POpen-market purchase Common Stock | +600 | $6.51 | $3,906 | 35,875 | Nov 17, 2023 |
| Nov 16, 2023 | PLSE Pulse Biosciences, Inc. | POpen-market purchase Common Stock | +12 | $6.50 | $78 | 35,887 | Nov 17, 2023 |
| Oct 23, 2023 | PLSE Pulse Biosciences, Inc. | AGrant or award Stock Option (right to buy)derivative | +130,000 | $0.00 | $0 | 130,000 | Nov 3, 2023 |
| Nov 1, 2023 | PLSE Pulse Biosciences, Inc. | JOther Stock Option (right to buy)derivative | -130,000 | $0.00 | $0 | 0 | Nov 3, 2023 |
| Nov 1, 2023 | PLSE Pulse Biosciences, Inc. | AGrant or award Stock Option (right to buy)derivative | +460,000 | $0.00 | $0 | 460,000 | Nov 3, 2023 |
Questions about Kevin Patrick Danahy
Answered from the filings on this page, as of the latest one.
Is Kevin Patrick Danahy buying or selling?
In the last 12 months Kevin Patrick Danahy reported 0 open-market buys worth $0 and 3 open-market sells worth $2.9M on SEC Form 4; the latest was sold $118k of PLSE on Feb 18, 2026. Grants, option exercises and tax withholding are not counted.
How did Kevin Patrick Danahy's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Kevin Patrick Danahy has 0.
Where does Kevin Patrick Danahy file Form 4?
Kevin Patrick Danahy has filed Form 4 at PLSE (Pulse Biosciences, Inc.) as Chief Executive Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.